Dublin-based drugmaker Mallinckrodt Plc has agreed to buy privately held Ikaria Inc, a manufacturer best known for its inhaled nitric oxide (iNO) delivery device, for $2.3 billion.
The deal gives Mallinckrodt access to INOmax, which Ikaria says is the only approved product to treat hypoxic respiratory failure in infants. The device that delivers nitric oxide has been available in the market for about a decade and a half.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management